CD86 and cancer: Ultimately, HDIs may regulate cancer cell immunogenicity by upregulating molecules participating in T-cell and natural killer cell activation, such as MHC class I and II, CD80/CD86, and MHC class I chain-related molecules (MICA/MICB) [55].